Wall Street analysts expect Cytosorbents Corp (NASDAQ:CTSO) to announce ($0.14) earnings per share for the current fiscal quarter, according to Zacks. Five analysts have issued estimates for Cytosorbents’ earnings, with the highest EPS estimate coming in at ($0.11) and the lowest estimate coming in at ($0.18). Cytosorbents reported earnings per share of ($0.10) during the same quarter last year, which would indicate a negative year over year growth rate of 40%. The company is expected to issue its next quarterly earnings report on Tuesday, November 5th.
According to Zacks, analysts expect that Cytosorbents will report full year earnings of ($0.53) per share for the current fiscal year, with EPS estimates ranging from ($0.62) to ($0.44). For the next financial year, analysts expect that the company will post earnings of ($0.32) per share, with EPS estimates ranging from ($0.64) to ($0.08). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research analysts that cover Cytosorbents.
Cytosorbents (NASDAQ:CTSO) last released its quarterly earnings data on Tuesday, August 6th. The medical research company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.03. Cytosorbents had a negative net margin of 72.43% and a negative return on equity of 105.97%. The business had revenue of $6.23 million during the quarter, compared to the consensus estimate of $6.53 million.
Several research analysts have commented on the stock. HC Wainwright reissued a “buy” rating on shares of Cytosorbents in a report on Wednesday, August 7th. ValuEngine raised shares of Cytosorbents from a “hold” rating to a “buy” rating in a report on Wednesday, October 2nd. Maxim Group set a $14.00 price objective on shares of Cytosorbents and gave the company a “buy” rating in a report on Wednesday, August 7th. Finally, B. Riley set a $12.00 price objective on shares of Cytosorbents and gave the company a “buy” rating in a report on Friday, July 19th. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $13.67.
In related news, CFO Kathleen P. Bloch acquired 6,500 shares of the company’s stock in a transaction on Friday, August 16th. The stock was acquired at an average price of $4.83 per share, with a total value of $31,395.00. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 5.60% of the stock is owned by corporate insiders.
Several large investors have recently made changes to their positions in CTSO. Skylands Capital LLC increased its holdings in shares of Cytosorbents by 7.0% in the second quarter. Skylands Capital LLC now owns 680,600 shares of the medical research company’s stock worth $4,499,000 after buying an additional 44,550 shares during the period. Advisor Group Inc. increased its holdings in shares of Cytosorbents by 15.8% in the second quarter. Advisor Group Inc. now owns 33,170 shares of the medical research company’s stock worth $219,000 after buying an additional 4,530 shares during the period. Charles Schwab Investment Management Inc. increased its holdings in shares of Cytosorbents by 31.4% in the second quarter. Charles Schwab Investment Management Inc. now owns 81,270 shares of the medical research company’s stock worth $538,000 after buying an additional 19,439 shares during the period. Avenir Corp increased its holdings in shares of Cytosorbents by 66.6% in the second quarter. Avenir Corp now owns 145,300 shares of the medical research company’s stock worth $960,000 after buying an additional 58,060 shares during the period. Finally, Sargent Investment Group LLC increased its holdings in Cytosorbents by 15.9% during the 2nd quarter. Sargent Investment Group LLC now owns 333,910 shares of the medical research company’s stock valued at $2,207,000 after purchasing an additional 45,840 shares during the period. 26.27% of the stock is owned by hedge funds and other institutional investors.
Shares of CTSO traded up $0.12 during midday trading on Thursday, hitting $4.79. 84,593 shares of the company traded hands, compared to its average volume of 147,884. The firm has a 50 day moving average of $4.93 and a 200-day moving average of $6.14. Cytosorbents has a 52 week low of $3.68 and a 52 week high of $12.00. The stock has a market cap of $150.84 million, a price-to-earnings ratio of -8.55 and a beta of 1.70. The company has a debt-to-equity ratio of 0.87, a quick ratio of 3.00 and a current ratio of 3.21.
Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology worldwide. The company's flagship product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.